Impact of IL28B gene polymorphisms rs8099917 and rs12980275 on response to pegylated interferon-α/ribavirin therapy in chronic hepatitis C genotype 4 patients

作     者：Mahmoud A Khattab Hend M Abdelghany Maggie M Ramzy Rasha M Khairy 

作者机构：Departments of Internal MedicineFaculty of MedicineMinia UniversityEl-Minia 61519Egypt Biochemistry MicrobiologyFaculty of MedicineMinia UniversityEl-Minia 61519Egypt 

出 版 物：《The Journal of Biomedical Research》 (生物医学研究杂志（英文版）)

年 卷 期：2016年第30卷第1期

页      面：40-45页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：IL 28B polymorphism hepatitis C virus sustained viral response genotype 

摘      要：Host genetic factors may predict the outcome and treatment response in hepatitis C virus（HCV）*** of these factors is the single nucleotide polymorphisms of the interleukin 28B（IL28B）*** sought to evaluate the outcome of pegylated interferon and ribavirin therapy in association with IL-28B rs8099917 and rsl2980275 in patients infected with HCV genotype 4.A total of 180 patients with chronic hepatitis C were selected from Egyptians who have received combined therapy with pegylated interferon and ribavirin for 6 months and their response was evaluated after follow-up at 0,6,12,24 and 48 weeks from the beginning of the *** samples were collected from responders and *** DNA was extracted from whole blood and genotyping was carried out by polymerase chain reaction and restriction fragment length polymorphism（PCR-RFLP）.Our results showed that TT genotype of rs8099917 was associated with higher sustained viral response（SVR）rates and G allele represented a risk factor for failure of response（OR=3.7,CI=1.8：7.64）while rs12980275 was not significantly associated with SVR in genotype 4 Egyptian *** determination of 1L-28B SNPs may be useful in enhancing correct prediction of SVR achievement in treating this group of genotype 4 patients.